Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Jan
06
Today In Oncology
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Study Finds Patients With Colon Cancer and Obesity Receiving GLP-1 RAs Had Significantly Reduced Risk of Mortality
A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus
Physical Activity and Fatigue QOL in Nonmetastatic CRC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo